NS-2359 / Saniona - LARVOL DELTA

[VIRTUAL] NS2359 for the Treatment of Cocaine Use Disorder (CPDD 2021) - "2 mg of NS2359 as the tartrate salt was well tolerated but was no more efficacious than placebo in promoting abstinence from cocaine in patients with Cocaine Use Disorder."

Understanding the Polypharmacological Profiles of Triple Reuptake Inhibitors by Molecular Simulation. (PubMed, ACS Chem Neurosci) - "In this study, the solved X-ray crystallographic structure of hSERT in complex with escitalopram was used as a basis for modeling nine complexes of three representative TRIs (SEP225289, NS2359, and EB1020) bound to their corresponding targets. Furthermore, the combined protein-ligand interaction fingerprint and residue energy contribution analysis indicated that several conserved and nonconserved "Warm Spots" such as S149, V328, and M427 in hDAT, F317, F323, and V325 in hNET and F335, F341, and V343 in hSERT were responsible for the TRI-binding selectivity. These findings provided important information for rational design of a single drug with better polypharmacological profiles through modulating multiple targets."

Journal

Trial Of NS2359 For The Treatment of Cocaine Dependence (clinicaltrials.gov) - P2; N=55; Completed; Sponsor: University of Pennsylvania; Recruiting ➔ Completed; N=80 ➔ 55; Trial completion date: Jul 2021 ➔ Oct 2020; Trial primary completion date: Jun 2021 ➔ Mar 2020

Clinical • Enrollment change • Trial completion • Trial completion date • Trial primary completion date

Trial Of NS2359 For The Treatment of Cocaine Dependence (clinicaltrials.gov) - P2; N=80; Recruiting; Sponsor: University of Pennsylvania; Trial completion date: Jul 2019 ➔ Jul 2021

Trial completion date

Saniona publishes its interim report for the first quarter 2019 (GlobeNewswire, Saniona AB) - "Saniona successfully completed a full regulatory toxicological program for its first in class compound, SAN711, which offers a new treatment paradigm for itching and neuropathic pain. Saniona has scaled-up the manufacturing process, produced the material for clinical studies and the program is now ready for Phase 1 studies."

Clinical • Clinical data • Commercial • New trial • Preclinical